Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06591091 · ClinicalTrials.gov registry record · Phase 2
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT06591091 is a Phase 2 study that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 80 participants.
The verdict
NCT06591091, a Phase 2 study, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.
Interventions
- DRUG Placebo
- DRUG Clemastine Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-10 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06591091
The ClinicalTrials.gov registry entry for NCT06591091 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06591091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06591091 about?
NCT06591091 is a clinical study titled "Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression". The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory ...
What is the current status of trial NCT06591091?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-10. Estimated completion is 2026-12.
What interventions are being tested in trial NCT06591091?
The interventions under investigation include: Placebo (DRUG), Clemastine Fumarate (DRUG).
Who is sponsoring clinical trial NCT06591091?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.